Soligenix Submits Type A Meeting Request To US FDA To Review Proposed Study Design For A Second Phase 3 Study Evaluating HyBryte In The Treatment Of Cutaneous T-Cell Lymphoma
Soligenix Submits Type A Meeting Request To US FDA To Review Proposed Study Design For A Second Phase 3 Study Evaluating HyBryte In The Treatment Of Cutaneous T-Cell Lymphoma
Soligenix 向美国食品药品管理局提交了 A 类会议申请，要求审查评估Hybryte在皮肤T细胞淋巴瘤治疗中的第二项3期研究的拟议研究设计
Soligenix Submits Type A Meeting Request To US FDA To Review Proposed Study Design For A Second Phase 3 Study Evaluating HyBryte In The Treatment Of Cutaneous T-Cell Lymphoma
Soligenix 向美国食品药品管理局提交了 A 类会议申请，要求审查评估Hybryte在皮肤T细胞淋巴瘤治疗中的第二项3期研究的拟议研究设计